NME Approvals Dropped In 2005, While Review Times Remained Stable
This article was originally published in The Pink Sheet Daily
Executive Summary
Standard review times dropped from 24.7 months in 2004 to 23 months in 2005, according to FDA's review of agency accomplishments.
You may also be interested in...
PDUFA Performance In The FDAAA Era: Over One Third Of Novel 2009 CDER Approvals Took Advantage Of Relaxed User Fee Goal Interregnum
CDER met the user fee goals of almost two-thirds of new molecular entities and novel therapeutic biologics approved in 2009, even at the height of the almost two-year period when Office of New Drugs Director John Jenkins allowed reviewers to miss Prescription Drug User Fee Act action dates due to workload and resource constraints
Lipitor Pricing Offsets Loss In Prescription Volume, Pfizer Says
Declines in Lipitor's prescription volume due to the presence of generic simvastatin are being offset by price increases, Pfizer says